Carbamazepine Treatment for Cocaine Dependence - 5
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders
Intervention: Carbamazepine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
James Cornish, M.D., Principal Investigator, Affiliation: University of Pennsylvania
Summary
The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine
dependence.
Clinical Details
Official title: Carbamazepine Treatment for Cocaine Dependence
Study design: Treatment
Eligibility
Minimum age: 21 Years.
Maximum age: 51 Years.
Gender(s): Both.
Criteria:
Please contact site for information.
Locations and Contacts
University of Pennsylvania, Philadelphia, Pennsylvania 19104 6178, United States
Additional Information
Last updated: June 23, 2005
|
